ANTCF - Another psychedelics company goes public on U.S. exchange

New York-based MindMed will begin trading on the Nasdaq today, becoming the second psychedelic company ever to go public on a major American exchange. Shroom drug developer Compass Pathways (CMPS) debuted only six months ago, while another "drug growth platform,"called Atai Life Sciences, filed to go public last week. "I think that the psychedelics industry could be much bigger than the cannabis industry because it's going to attract institutional capital and already is starting to," MindMed co-founder JR Rahn declared. "It's also going to be a more concentrated space because the barriers to entry are much higher."Backdrop: MindMed (MMEDF) went public last year on Toronto's NEO Exchange, after failing to secure a second round of VC funding. "VCs had blinders on when they saw those three letters: LSD," Rahn continued. "We got laughed out of most rooms... Where we found patient capital was up in Toronto." The new move to

For further details see:

Another psychedelics company goes public on U.S. exchange